Soleno Therapeutics (SLNO) Revenue (2015 - 2026)
Soleno Therapeutics (SLNO) reported Revenue of $94.6 million for Q1 2026, up 3.13% on a QoQ basis from $91.7 million in Q4 2025.
Soleno Therapeutics (SLNO) has 5 years of Revenue data on file, last reported at $94.6 million in Q1 2026.
- Quarterly Revenue changed N/A year-over-year to $94.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285.0 million (changed N/A YoY) and the FY2025 annual result came in at $190.4 million, changed N/A from the prior year.
- Revenue advanced to $94.6 million in Q1 2026 per SLNO's latest filing, from $91.7 million in the prior quarter.
- Across five years, Revenue topped out at $94.6 million in Q1 2026 and bottomed at $32.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 94.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.60 Mn |
| Dec 31, 2025 | 91.73 Mn |
| Sep 30, 2025 | 66.02 Mn |
| Jun 30, 2025 | 32.66 Mn |
| Jun 30, 2017 | 1,000.00 |
| Mar 31, 2017 | 265,000.00 |
| Dec 31, 2016 | 1.45 Mn |
| Sep 30, 2016 | 329,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Mar 31, 2016 | 447,000.00 |
| Dec 31, 2015 | 73,917.00 |
| Sep 30, 2015 | 27,000.00 |
| Jun 30, 2015 | 97,000.00 |
| Mar 31, 2015 | 22,000.00 |